

[to Content](#)



- [For Parents](#)
- [For Healthcare Providers](#)
- [Current Studies](#)
- [Future and Completed Studies](#)
- [Participating Hospitals](#)
- [Publications](#)
- [Helpful Resources](#)

- [Study Basics](#)
- [Study Design](#)
- [Primary Endpoint](#)
- [Secondary Endpoint](#)
- [Inclusion Criteria](#)
- [Exclusion Criteria](#)

### Marfan Study Basics

Marfan is a Trial of Beta Blocker (BB) Therapy (Atenolol) vs. Angiotensin II Receptor Blocker (ARB) Therapy (Losartan) in Individuals with Marfan Syndrome (MFS). The target number of participants is 604. The accrual period is approximately 6 years with recruitment to begin in the Fall of 2006.

### Study Design

A Phase III, *randomized*, double-blind, multi-center trial to compare the effect of BB therapy to that of ARB therapy on rates of aortic growth and progression of aortic regurgitation in individuals with MFS. Patients are followed for three years after randomization.

### Primary Endpoint

Rate of change in aortic root body surface area adjusted Z-score.

### Secondary Endpoints

1. Frequency of combined endpoint: aortic dissection, aortic root surgery or death
2. Rate of change of mitral regurgitation
3. Rate of progression of left ventricular dilation and dysfunction
4. Rate of change in central aortic stiffness indices
5. Long bone overgrowth and weight gain
6. Comparison of adverse drug reactions between groups

### Inclusion Criteria

1. 6 months to 25 years of age
2. Diagnosis of MFS according to Ghent criteria
3. Aortic root Z-score >3.0

### Exclusion Criteria

1. Prior aortic surgery
2. Aortic root dimension at the sinuses of Valsalva >5 cm.
3. Planned aortic surgery within 6 months of enrollment
4. Aortic dissection
5. Shprintzen-Goldberg syndrome
6. Loeys-Dietz syndrome
7. Therapeutic rather than prophylactic use of ACE-I, BB, or calcium channel blocker (e.g. for arrhythmia, ventricular dysfunction or valve regurgitation)
8. History of angioedema while taking ACE-I or BB
9. Intolerance to losartan or other ARB that resulted in termination of therapy
10. Intolerance to atenolol or other BB that resulted in termination of therapy
11. Renal dysfunction
12. Asthma of sufficient severity to preclude use of a BB
13. Diabetes mellitus
14. Pregnancy or planned pregnancy within 36 months of enrollment
15. Inability to complete study procedures including history of poor acoustic windows (inability to obtain accurate measurement of aortic root)



= glossary definition

[↑ Back to Top](#)

[↑ Back to Top](#)

[↑ Back to Top](#)



Department of Health and Human Services



National Institutes of Health



National Heart, Lung, and Blood Institute